Sei Investments Co. Sells 15,486 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

Sei Investments Co. lowered its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 41.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 21,451 shares of the biotechnology company's stock after selling 15,486 shares during the period. Sei Investments Co.'s holdings in Viking Therapeutics were worth $863,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Raymond James Financial Inc. acquired a new stake in Viking Therapeutics in the 4th quarter worth approximately $24,888,000. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Viking Therapeutics by 137.0% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 375,222 shares of the biotechnology company's stock worth $15,099,000 after buying an additional 216,873 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Viking Therapeutics by 29.9% during the 3rd quarter. Principal Financial Group Inc. now owns 593,528 shares of the biotechnology company's stock worth $37,576,000 after buying an additional 136,729 shares during the period. Steward Partners Investment Advisory LLC raised its holdings in Viking Therapeutics by 42.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 224,409 shares of the biotechnology company's stock worth $9,030,000 after acquiring an additional 66,358 shares during the period. Finally, Stifel Financial Corp raised its holdings in Viking Therapeutics by 92.1% in the 3rd quarter. Stifel Financial Corp now owns 131,348 shares of the biotechnology company's stock worth $8,316,000 after acquiring an additional 62,956 shares during the period. Institutional investors own 76.03% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

VKTX has been the topic of a number of research analyst reports. Citigroup began coverage on Viking Therapeutics in a report on Friday, February 7th. They issued a "neutral" rating and a $38.00 target price on the stock. Piper Sandler cut their price objective on shares of Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating for the company in a research report on Thursday, February 6th. Raymond James lifted their target price on Viking Therapeutics from $122.00 to $125.00 and gave the stock a "strong-buy" rating in a research report on Thursday, February 6th. HC Wainwright reaffirmed a "buy" rating and issued a $102.00 price target on shares of Viking Therapeutics in a report on Wednesday, March 26th. Finally, B. Riley reissued a "buy" rating and set a $96.00 price objective (down previously from $109.00) on shares of Viking Therapeutics in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $89.75.

Insider Buying and Selling at Viking Therapeutics

In other Viking Therapeutics news, Director Sarah Kathryn Rouan purchased 1,240 shares of the stock in a transaction dated Monday, March 31st. The stock was bought at an average price of $24.15 per share, for a total transaction of $29,946.00. Following the transaction, the director now directly owns 1,240 shares in the company, valued at $29,946. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 4.70% of the company's stock.

Viking Therapeutics Stock Up 3.3 %

VKTX traded up $0.70 during trading on Friday, hitting $22.22. The company's stock had a trading volume of 2,962,262 shares, compared to its average volume of 3,982,300. The firm's 50 day moving average price is $27.71 and its two-hundred day moving average price is $43.20. The stock has a market capitalization of $2.49 billion, a price-to-earnings ratio of -22.22 and a beta of 0.84. Viking Therapeutics, Inc. has a 12 month low of $18.92 and a 12 month high of $81.86.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same quarter in the previous year, the business posted ($0.25) EPS. On average, sell-side analysts forecast that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.